| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30006414 | HIV | ENSG00000129484.14 | protein_coding | PARP2 | No | No | 10038 | Q9UGN5 |
| TVIS30035882 | HIV | ENSG00000129484.14 | protein_coding | PARP2 | No | No | 10038 | Q9UGN5 |
| TVIS30035883 | HIV | ENSG00000129484.14 | protein_coding | PARP2 | No | No | 10038 | Q9UGN5 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PARP2 |
|---|---|
| DrugBank ID | DB12332 |
| Drug Name | Rucaparib |
| Target ID | BE0003798 |
| UniProt ID | Q9UGN5 |
| Regulation Type | inhibitor |
| PubMed IDs | 28790837; 27087632 |
| Citations | Dockery LE, Gunderson CC, Moore KN: Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. Onco Targets Ther. 2017 Jun 19;10:3029-3037. doi: 10.2147/OTT.S114714. eCollection 2017.@@Jenner ZB, Sood AK, Coleman RL: Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. Future Oncol. 2016 Jun;12(12):1439-56. doi: 10.2217/fon-2016-0002. Epub 2016 Apr 18. |
| Groups | Approved; Investigational |
| Direct Classification | 2-phenylindoles |
| SMILES | CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3 |
| Pathways | |
| PharmGKB | PA166163418 |
| ChEMBL | CHEMBL1173055 |
